Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK Arexvy protects from RSV over 3 full seasons
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case for its first-to-market respiratory syncytial virus (RSV) shot Arexvy. | GSK on Tuesday unveiled fresh data from the late-stage AReSVi-006 study of Arexvy in RSV-triggered lower respiratory tract disease in older adults over the span of three full RSV seasons.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
GSK hopes for Arexvy boost after positive Phase III data
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of Arexvy maintains 62.9% efficacy in preventing RSV-related lower respiratory tract disease (LRTD) and 67.
GSK, Pfizer seeing drop in demand for RSV vaccines: report
RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots. Read more here.
GSK's RSV vaccine Arexvy shows long-term protection in Phase 3 trial
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST 2024 Annual Meeting. In the Phase 3 trial, called AReSVi-006, a dose of Arexvy was 62.
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ages of 70 and 79 years.
GSK, Zantac
GSK to pay $2.2bn to settle Zantac lawsuits
GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of markets on Wednesday, the pharmaceuticals firm said it had reached an agreement with 10 firms who represent 93% of the Zantac (ranitidine) state court product liability cases pending against it in the US.
UK firm GSK to pay $2.2bn over Zantac cancer claims
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer. The firm announced that it has reached agreements with 10 law firms who represent around 80,
GSK Reaches $2.2 Bln Settlement Over Zantac Liability Cases
GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000)
1d
on MSN
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
cidrap.umn
12h
GSK RSV vaccine data suggest protection across 3 seasons
The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.
1d
on MSN
GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...
1d
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
McKnight's Long-Term Care News
1d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback